Your Habits Are Talking. Here's What They're Saying About You.

Artios Pharma Limited, a British biopharmaceutical company committed to realising the therapeutic potential of targeting the DNA damage response (DDR) in cancer, today announced the successful close of an oversubscribed €99 million ($115 million) Series D financing.The investors who supported the round include Andera Partners, Avidity Partners, EQT Life Sciences, Invus, IP Group plc, Janus Henders